309 related articles for article (PubMed ID: 28445973)
1. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector.
Liu Q; Yang Y; Tan X; Tao Z; Adah D; Yu S; Lu J; Zhao S; Qin L; Qin L; Chen X
Oncotarget; 2017 Apr; 8(15):24785-24796. PubMed ID: 28445973
[TBL] [Abstract][Full Text] [Related]
2. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
[TBL] [Abstract][Full Text] [Related]
3. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
Yoshikawa T; Nakatsugawa M; Suzuki S; Shirakawa H; Nobuoka D; Sakemura N; Motomura Y; Tanaka Y; Hayashi S; Nakatsura T
Cancer Sci; 2011 May; 102(5):918-25. PubMed ID: 21281401
[TBL] [Abstract][Full Text] [Related]
4.
Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
[TBL] [Abstract][Full Text] [Related]
5. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide.
Tada Y; Yoshikawa T; Shimomura M; Sawada Y; Sakai M; Shirakawa H; Nobuoka D; Nakatsura T
Int J Oncol; 2013 Oct; 43(4):1019-26. PubMed ID: 23903757
[TBL] [Abstract][Full Text] [Related]
6. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
[TBL] [Abstract][Full Text] [Related]
7. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
[TBL] [Abstract][Full Text] [Related]
9. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
[TBL] [Abstract][Full Text] [Related]
11. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.
Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C
Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999
[TBL] [Abstract][Full Text] [Related]
12. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
[TBL] [Abstract][Full Text] [Related]
13. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
Sawada Y; Yoshikawa T; Shimomura M; Iwama T; Endo I; Nakatsura T
Int J Oncol; 2015 Jan; 46(1):28-36. PubMed ID: 25354479
[TBL] [Abstract][Full Text] [Related]
14. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
[TBL] [Abstract][Full Text] [Related]
15. Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide.
Iwama T; Horie K; Yoshikawa T; Nobuoka D; Shimomura M; Sawada Y; Nakatsura T
Int J Oncol; 2013 Mar; 42(3):831-8. PubMed ID: 23354275
[TBL] [Abstract][Full Text] [Related]
16. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
17. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
[TBL] [Abstract][Full Text] [Related]
18. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
Nishimura Y; Nakatsura T; Senju S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
[TBL] [Abstract][Full Text] [Related]
19. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
20. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
